NovaBay Total Other Income Expense Net vs Total Operating Expenses Analysis
NBY Stock | USD 0.13 0.01 7.50% |
NovaBay Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating NovaBay Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether NovaBay Pharmaceuticals is a good investment. Please check the relationship between NovaBay Pharmaceuticals Total Other Income Expense Net and its Total Operating Expenses accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.
Total Other Income Expense Net vs Total Operating Expenses
Total Other Income Expense Net vs Total Operating Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of NovaBay Pharmaceuticals Total Other Income Expense Net account and Total Operating Expenses. At this time, the significance of the direction appears to have very week relationship.
The correlation between NovaBay Pharmaceuticals' Total Other Income Expense Net and Total Operating Expenses is 0.23. Overlapping area represents the amount of variation of Total Other Income Expense Net that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of NovaBay Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of NovaBay Pharmaceuticals' Total Other Income Expense Net and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Other Income Expense Net of NovaBay Pharmaceuticals are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Total Other Income Expense Net i.e., NovaBay Pharmaceuticals' Total Other Income Expense Net and Total Operating Expenses go up and down completely randomly.
Correlation Coefficient | 0.23 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Total Other Income Expense Net
Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Most indicators from NovaBay Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 18.2 M in 2024, whereas Tax Provision is likely to drop 0.00 in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.6M | 7.8M | 7.9M | 8.1M | Total Revenue | 8.4M | 14.4M | 14.7M | 10.0M |
NovaBay Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
NovaBay Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
NovaBay Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
Total Stockholder Equity | 973K | 12.3M | 10.2M | 10.6M | 3.3M | 5.3M | |
Other Assets | 477K | 912K | 476K | 489K | 562.4K | 461.6K | |
Common Stock Shares Outstanding | 618.3K | 1.0M | 1.2M | 1.6M | 4.2M | 4.4M | |
Liabilities And Stockholders Equity | 11.2M | 15.2M | 24.0M | 16.4M | 9.0M | 14.4M | |
Other Stockholder Equity | 125.7M | 148.0M | 150.9M | 165.1M | 176.4M | 185.2M | |
Total Liab | 10.2M | 2.9M | 13.8M | 5.8M | 5.7M | 7.1M | |
Other Current Liab | 993K | 1.4M | 803K | 917K | 570K | 541.5K | |
Total Current Liabilities | 5.7M | 2.8M | 3.4M | 4.3M | 4.3M | 4.1M | |
Property Plant And Equipment Net | 1.4M | 520K | 604K | 2.0M | 1.4M | 1.0M | |
Net Debt | (2.9M) | (11.4M) | (7.0M) | (3.3M) | (390K) | (409.5K) | |
Retained Earnings | (125.0M) | (136.1M) | (141.9M) | (158.2M) | (174.8M) | (166.1M) | |
Accounts Payable | 331K | 302K | 1.0M | 1.1M | 1.1M | 812.7K | |
Cash | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 6.0M | |
Non Current Assets Total | 1.8M | 996K | 10.8M | 5.1M | 1.9M | 2.0M | |
Cash And Short Term Investments | 6.9M | 12.0M | 7.5M | 5.4M | 3.1M | 3.0M | |
Common Stock Total Equity | 154K | 171K | 279K | 418K | 480.7K | 263.6K | |
Other Current Assets | 105K | 102K | 144K | 113K | 388K | 271.6K | |
Property Plant And Equipment Gross | 1.4M | 520K | 1.2M | 2.6M | 2.1M | 1.1M | |
Total Current Assets | 9.4M | 14.2M | 13.2M | 11.3M | 7.2M | 9.5M | |
Accumulated Other Comprehensive Income | (243K) | (509K) | (560K) | (275K) | (247.5K) | (259.9K) | |
Common Stock | 279K | 418K | 478K | 652K | 112K | 106.4K | |
Property Plant Equipment | 110K | 520K | 604K | 2.0M | 1.8M | 1.8M | |
Other Liab | 2.5M | 560K | 4.1M | 10.1M | 11.6M | 12.2M | |
Current Deferred Revenue | 822K | 730K | 1.3M | 1.8M | 946K | 1.2M | |
Non Current Liabilities Total | 4.6M | 87K | 10.4M | 1.6M | 1.4M | 2.6M | |
Short Term Debt | 3.5M | 416K | 305K | 453K | 1.6M | 1.7M | |
Non Currrent Assets Other | 77K | 2K | 476K | 489K | 21K | 20.0K | |
Net Receivables | 1.1M | 1.1M | 1.7M | 2.0M | 759K | 721.1K | |
Net Tangible Assets | 5.0M | 973K | 12.3M | (237K) | (213.3K) | (202.6K) | |
Retained Earnings Total Equity | (111.1M) | (115.0M) | (125.0M) | (136.1M) | (122.5M) | (116.3M) | |
Capital Surpluse | 125.7M | 148.0M | 150.9M | 165.1M | 189.8M | 118.8M | |
Inventory | 492K | 608K | 3.2M | 3.4M | 2.9M | 3.0M | |
Non Current Liabilities Other | 198K | 4.6M | 561K | 334K | 300.6K | 285.6K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.Note that the NovaBay Pharmaceuticals information on this page should be used as a complementary analysis to other NovaBay Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for NovaBay Stock analysis
When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |
Is NovaBay Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NovaBay Pharmaceuticals. If investors know NovaBay will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NovaBay Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.96) | Revenue Per Share 3.494 | Quarterly Revenue Growth 0.023 | Return On Assets (0.25) | Return On Equity (1.39) |
The market value of NovaBay Pharmaceuticals is measured differently than its book value, which is the value of NovaBay that is recorded on the company's balance sheet. Investors also form their own opinion of NovaBay Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is NovaBay Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NovaBay Pharmaceuticals' market value can be influenced by many factors that don't directly affect NovaBay Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NovaBay Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if NovaBay Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NovaBay Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.